A retrospective consecutive case series using mineralized allograft combined with recombinant human platelet-derived growth factor BB to treat moderate to severe osseous lesions.
This retrospective case series reports on the use of freeze-dried bone allograft (FDBA) combined with a purified recombinant protein of platelet-derived growth factor BB (PDGF-BB) for the treatment of periodontal intraosseous defects in 50 consecutive patients. The mean pretreatment measurements for clinical attachment level and probing depth were 7.9 ± 1.6 mm and 7.8 ± 1.4 mm, respectively. At 6 months, mean clinical attachment level was 3.9 ± 1.4 mm, reflecting an improvement of 4.1 ± 1.3 mm, whereas mean probing depth was reduced to 3.0 ± 1.2 mm, corresponding to a reduction of 4.8 ± 1.4 mm. These clinical results indicate that the combined use of FDBA and PDGF-BB can lead to substantial improvements in clinical parameters.